US Stocks Movement: LB Pharmaceuticals surged on October 9 as Canaccord initiated a Buy rating and LB-102 entered Phase III trials
Bitget异动解读2026/10/09 13:45Interpretation of LB Pharmaceuticals Surge on October 9
Keywords: Canaccord Buy, LB-102 Phase III
1. On October 9, Canaccord Genuity initiated coverage on LB Pharmaceuticals with a “Buy” rating and set a target price of $65, serving as a direct news catalyst for the day.
2. On October 6, the company announced it will hold an R&D Day on October 27, focusing on LB-102 and its schizophrenia program; topline results from the pivotal NOVA-2 Phase III trial of LB-102 for schizophrenia are expected to be released in the first half of 2027.
3. On August 11, the company disclosed that LB-102 is in Phase III clinical trials for schizophrenia and Phase II for bipolar depression, and plans to expand into other neuropsychiatric indications; as of June 30, cash, cash equivalents, and marketable securities totaled $327.8 million.
(Disclaimer: This content was generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barclays assigns Boeing an overweight rating with a target price of $300
Barclays assigns an overweight rating to Boeing (BA.US) with a price target of $300.
U.S. stocks move: Fastly surges on October 9—Oppenheimer initiates buy rating, AI traffic, and edge cloud.
Morgan Stanley optimistic about AI semiconductor market: TSMC has strong certainty, ACM Research and Silicon Motion Technology have over 50% upside potential in target price
According to Odaily, in its latest report covering the Greater China semiconductor sector, Morgan Stanley gave the AI semiconductor industry chain an "attractive" sector rating. Among investable US equities, TSMC (TSM.US) was identified by Morgan Stanley as the most certain beneficiary. Together with ACM Research (ACMR.US) and Silicon Motion (SIMO.US), it forms the core portfolio benefiting from the expansion of AI computing power.
Crypto prices
More
